Vanderbilt Center for Diabetes Translation Research

范德比尔特糖尿病翻译研究中心

• 批准号: 9186924
• 负责人: TOM A ELASY
• 金额: $ 67.64万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9186924
• 关键词: Academic Medical Centers; Award; Behavior Therapy; Behavioral; Caring; Clinical; Clinical Trials; Collaborations; Communities; Community Health; Community Outreach; Development; Diabetes Mellitus; Diabetes prevention; Direct Costs; Doctor of Medicine; Doctor of Philosophy; Foundations; Funding; Goals; Individual; Institution; K-Series Research Career Programs; Knowledge; Lead; Leadership; Manuscripts; Medial; Methods; Modification; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Population; Publishing; Research; Research Personnel; Risk; Secure; Services; Structure; Technology; Translational Research; Translations; United States National Institutes of Health; abstracting; base; cardiovascular risk factor; college; design; diabetes control; education research; effective intervention; ethnic minority population; glycemic control; health disparity; high risk; medical schools; meetings; prevent; programs; racial minority; success; type I and type II diabetes

Center Overview Project Summary/Abstract Clinical trials have established that glycemic control and cardiovascular risk factor modification can reduce the risk of complications of type 1 and type 2 diabetes. In addition, behavioral strategies have been shown to delay or prevent the development of type 2 diabetes in individuals at high risk for diabetes. Despite the clarity of evidence, many individuals with diabetes do not meet the recommended goals of diabetes care. There is an unequivocal gap between evidence and real-world diabetes prevention and treatment, and this gap is particular evident in many racial and ethnic minorities. Investigators at the Vanderbilt University Medical Center and Meharry Medical College propose a renewal to our Center for Diabetes Translation Research ( https://labnodes.vanderbilt.edu/cdtr ) to bridge this gap by building on our success in type II translation research. This renewal proposal is based on a highly productive initial five years and a plan for the next cycle that maintains continuity with our excellent leadership while introducing change to reflect the changing needs of our research base. During the past five years our research base has significantly enlarged (from 23 to 38), been well funded (annual direct costs from NIDDK alone of nearly five million), and published important manuscripts (136 cited). Our P&F program has been extremely successful (8 investigators funded for 30K/year for two years) in that four investigators have already received either a K award or a DP3 award and a fifth awardee has secured a RO1. We believe our P&F program, owing to the ability to leverage institutional matching funds and the ability to extend over two years, has been one of the most successful aspects of the Center. Our enrichment program is extensive and includes collaborations with multiple entities across campus. We propose to build on the excellence of the past five years by maintaining continuity in our core structure and leadership while introducing a new core (Behavioral Intervention Technologies and Services Core) and leader (Chandra Osborn, Ph.D.) to reflect the expanding research base that utilizes technology for behavioral interventions. We maintain a focus on health disparities through our long standing relationship with Meharry Medical College and build on that foundation by introducing a new leader (Consuelo Wilkins, M.D.) to lead our enrichment core. Dr. Wilkins leads the Meharry-Vanderbilt Alliance (https://medschool.vanderbilt.edu/meharry- vanderbilt/) which explicity promotes collaboration between our two institutions to promote clinical and community-engaged collaboration, education and research. These additions build on our theme of reducing health disparities while expanding on our efforts to advance knowledge in behavioral intervention technologies.

中心概述项目摘要/摘要 临床试验已经确定，血糖控制和心血管危险因素改变可以减少 1型和2型糖尿病并发症的风险。此外，行为策略已被证明延迟 或防止患有糖尿病高风险的个体中2型糖尿病的发展。尽管很清楚 证据，许多糖尿病患者不符合糖尿病护理的推荐目标。有一个 证据和现实世界中的糖尿病预防和治疗之间的明确差距，这一差距是特别的 在许多种族和少数民族中都有明显的看法。 范德比尔特大学医学中心和梅哈里医学院的调查人员提出了续签 我们的糖尿病翻译研究中心（https://labnodes.vanderbilt.edu/cdtr）通过 基于我们在II型翻译研究方面的成功。该更新建议基于高产 最初的五年和下一个周期的计划，它与我们出色的领导力保持连续性 引入更改以反映我们研究基础的不断变化的需求。在过去的五年中，我们的研究 基地已经大大扩大（从23到38），资金充分（仅NIDDK的年度直接费用 将近500万），并出版了重要的手稿（引用了136个）。我们的P＆F计划非常 成功（8名调查人员为两年/年提供了30k/年的资助），这四个调查人员已经收到 要么是K奖或DP3奖和第五名获奖者获得了RO1。我们相信我们的P＆F计划，欠款 具有利用机构匹配资金的能力和延长两年的能力，一直是 中心最成功的方面。我们的丰富计划是广泛的，包括合作 校园中有多个实体。 我们建议通过在我们的核心结构中保持连续性和 在引入新的核心（行为干预技术和服务核心）和领导者的同时领导领导 （Chandra Osborn，Ph.D.）反映了利用技术进行行为的不断扩展的研究基础 干预措施。我们通过与Meharry长期的关系保持着专注于健康差异 医学院并通过引入新的领导者（Consuelo Wilkins，M.D。）来领导我们的基金会以领导我们 富集核心。威尔金斯博士领导了Meharry-Vanderbilt联盟（https://medschool.vanderbilt.edu/meharry-- 范德比尔特/）明确促进了我们两个机构之间的合作，以促进临床和 社区参与的合作，教育和研究。这些补充基于我们减少的主题 健康差异，同时扩大了我们促进行为干预技术知识的努力。